Selective neuromuscular blocks and chemoneurolysis in the localized treatment of spasticity.

Details

Ressource 1Request a copy Sous embargo indéterminé.
State: Public
Version: Final published version
License: Not specified
Serval ID
serval:BIB_F4ADA1F5BA06
Type
Article: article from journal or magazin.
Collection
Publications
Title
Selective neuromuscular blocks and chemoneurolysis in the localized treatment of spasticity.
Journal
Europa Medicophysica
Author(s)
Carda S., Molteni F.
ISSN
0014-2573 (Print)
ISSN-L
0014-2573
Publication state
Published
Issued date
2004
Peer-reviewed
Oui
Volume
40
Number
2
Pages
123-130
Language
english
Notes
Publication types: Journal Article Publication Status: ppublish
Abstract
Selective neuromuscular blocks and chemoneurolysis are currently the most widespread therapies for treating localized or locoregional spasticity. Both procedures present advantages and disadvantages. The main advantages of BTX-A are its relative ease of use, low incidence of side effects, reversibility and elevated efficacy. Its disadvantages are the limited maximum dose, which does not permit the treatment of many muscles simultaneously, especially if they are large, and its relatively high cost. Phenol neurolysis has a low cost, elevated efficacy in the control of pathologic muscle overactivity, and long duration of effect. Its disadvantages are the risk of injury to the vascular and sensory structures and the difficulty in performing the procedure. The risks associated with neurolysis have led to an increasing interest in and use of BTX-A, making it one of the most widely used therapies in treating localized spasticity. From the perspective of a balanced benefit-risk analysis, a viable option for some cases may be to combine phenol neurolysis for treating spasticity in large proximal muscles and BTX-A for treating hypertonia in small distal muscles.
Pubmed
Create date
25/03/2013 18:23
Last modification date
15/07/2020 6:26
Usage data